Article citationsMore>>

Fensterer, H., Schade-Brittinger, C., Müller, H.H., Tebbe, S., Fass, J., Lindig, U., et al. (2013) Multicenter Phase II Trial to Investigate Safety and Efficacy of Gemcitabine Combined with Cetuximab as Adjuvant Therapy in Pancreatic Cancer (ATIP). Annals of Oncology: Official Journal of the European Society for Medical Oncology, 24, 2576-2581.
https://doi.org/10.1093/annonc/mdt270

has been cited by the following article:

• TITLE: Cadherin 11 Expression Correlates with Pancreatic Carcinogenesis and Clinical Stage in Patients with Pancreatic Cancer

  AUTHORS: Lian-Qiang Han, Yang Tan, Qi Yang, Ming-Xian Yan

  KEYWORDS: Cadherin 11, Pancreatic Cancer, Prognosis

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.7, July 7, 2023

  ABSTRACT: Objective: The main purpose was to investigate expression of CDH11 in pancreatic tissues and analyze its relations with clinical characteristics of patients with pancreatic cancer (PC). Methods: Expression of CDH11 in cancerous tissues and cancer adjacent tissues were detected by immunohistochemistry staining, and their associations with clinical characteristics were analyzed. The text mining methods were used to assist the study of the effect of CDH11 on prognosis. Results: A total of 79 patients with PC were enrolled in the study, including 51 (64.6%) men and 28 (35.4%) women with a median age of 62 (41 - 84). The CDH11 expression in cancerous tissues was higher than that in adjacent tissues and the expression of CDH11 in both tissues was positively correlated (P 0.999; stage II vs III & IV, P = 0.308). A higher level of CDH11 expression correlated with worse overall survival (OS) time (P = 0.015). Conclusion: CDH11 may be involved in the development of early PC and lead to poor prognosis and could be a new target molecule for early diagnosis and treatment of PC.